Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: A comparative study

Chinese Journal of Cancer

Volumn 29, Issue 2, 2010, Pages 172-177

  Hao, Ming Zhi ^a   Lin, Hai Lan ^a   Chen, Qiang ^a   Ye, Yun Bin ^a   Chen, Qi Zhong ^a   Chen, Ming Shui ^a  

^a FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

Author keywords

Chemoembolization; Cytokine induced killer; Liver neoplasm; Overall survival; Progression free survival

Indexed keywords

FLOXURIDINE; GEMCITABINE; IODINATED POPPYSEED OIL; OXALIPLATIN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; CHEMOEMBOLIZATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG EFFICACY; FEMALE; HUMAN; INOPERABLE CANCER; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 79955835802     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10410     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000 [J]. Int J Cancer, 2001,94(2):153-156.
2. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial [J]. Lancet, 2002,359(9319):1734-1739.
3. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatology, 2002,35(5):1164-1171.
4. Zoll B, Lefterova P, Csipai M, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7, or-12 [J].Cancer Immunol Immunother, 1998,47(4):221-226.
5. Du QY, Wang FS, Xu DP, et al. Cytotoxic effects of CIK against hepatocellular carcinoma cells in vitro [J]. Shijie Huaren Xiaohua Zazhi, 2000,8(8):863-866. [in Chinese]
6. Marten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells [J]. Haematologica, 2001,86(10):1029-1037.
7. Alvarnas JC, Linn YC, Hope EG, et al. Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation [J]. Biol Blood Marrow Transplant, 2001,7(4):216-222.
8. Hoffman DM, Gitlitz BJ, Belldegrun A, et al. Adoptive cellular therapy [J]. Semin Oncol, 2000,27(2):221-233.
9. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, perspectives [J]. J Leukoc Biol, 1998,64(4):419-426.
10. Yang BH. The Diagnosing and Staging National Standards for hepatocellular carcinoma [J]. Zhonghua Ganzangbing Zazhi, 2001,9(6): 324. [in Chinese].
11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival [J]. Hepatology, 2003,37(2):429-442.
12. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatology, 2002,35(5):1164-1171.
13. Chen XM, Luo PF, Lin HH, et al. Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma [J].Chin J Cancer, 2004,23(7):829-832. [in Chinese]
14. Quan XY, Yu CT, Peng ZG, et al. CT study of development of hepatic cell carcinoma after hepatic arterial chemoembolization with lipiodol [J]. J Pract Radiol, 2000,16(1):21-23. [in Chinese]
15. Dai X, Han MJ, Su HY, et al. Study of recurrence and metastatic patterns of hepatic cellular carcinoma after transcatheter arterial chemoembolization [J]. J Chin Clin Med Imaging, 2004,15(11):613-615. [in Chinese]
16. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells [J]. J Gastroenterol Hepatol, 2002,17(8):889-896.
17. Wang FS, Liu MX, Zhang B, et al. Antitumor activities of human autologous cytokine-induced killer (CIK)cells against hepatocellular carcinoma cells in vitro and in vivo [J].World J Gastroenterol, 2002,8(3): 464-468.
18. Shi M, Zhang B, Tang ZR, et al. Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients [J].Zhonghua Yi Xue Za Zhi, 2003,83(23):2049-2053. [in Chinese]
19. Shi M, Yao L, Wang FS, Lei ZY, et al. Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy [J]. Zhonghua Zhong Liu Za Zhi, 2004,26(8):465-468. [in Chinese]
20. Zhou QM, Wu PH, Zhao M, et al. Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma [J]. Ai Zheng, 2006,25 (11):1414-1418. [in Chinese]
21. Zhao M, Wu PH, Zeng YX, et al. Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial [J]. Zhonghua Yi Xue Za Zhi, 2006,86(26):1823-1828. [in Chinese]
22. Zhang YS, Yuan FJ, Jia GF, et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R [J]. World J Gastroenterol, 2005,11(22):3339-3345.
23. Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations [J]. J Immunother, 2001,24(6):502-510.
24. Lu W, Li YH, He XF, et al. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma [J]. Di Yi Jun Yi Da Xue Xue Bao, 2002,22(6): 524-526. [in Chinese]
25. Puccio M, Nathanson L. The cancer cachexia syndrome. The cancer cachexia syndrome [J]. Semin Oncol, 1997,24(3):277-287